Hemogenyx Pharmaceuticals Stock Jumps: Partners with Made Scientific to Advance CAR-T Therapy

Hemogenyx Pharmaceuticals plc (LON: HEMO) shares surged more than 30% on Monday after the company announced a manufacturing partnership with Made Scientific, a U.S.-based cell therapy contract development and manufacturing organization (CDMO), to accelerate the development of HG-CT-1, its autologous Chimeric Antigen Receptor T-cell (CAR-T) therapy.

The collaboration aims to expedite the ongoing Phase I clinical trial for adult patients with relapsed/refractory acute myeloid leukemia (r/r AML) and potentially include pediatric cohorts.

HEMO shares have risen substantially in the last month.

Under the agreement, Hemogenyx will utilize Made Scientific's expertise in CAR-T cell therapy technology transfer and manufacturing at its GMP facilities in New Jersey.

The facilities are said to be equipped to handle both clinical and commercial supply of cell therapies. The markets are reacting positively to the news, viewing it as a significant step towards commercializing HG-CT-1.

The company added that progress in the Phase I trial has shown promising early clinical data, bolstering confidence in the therapy's safety and potential efficacy.

This partnership with Made Scientific is expected to further streamline the manufacturing process, a critical factor in bringing novel therapies to market.

CEO & Co-Founder of Hemogenyx Pharmaceuticals, Dr. Vladislav Sandler, commented: “Partnering with a trusted CDMO like Made Scientific is essential to the success of HG-CT-1, our lead CAR-T therapy. Made's expertise in cell therapy manufacturing will be instrumental in driving the continued progress of this potentially breakthrough therapy for patients with relapsed or refractory AML, fully in line with our identity as a life-saving company.”